Search research articles
Contact Us
Filters
Showing results (261-270 of 316) with videos related to
Page
of 32
Sort By:
Arthritis and Rheumatism
|
July 31, 2013
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus
Jacek C Szepietowski, Surasak Nilganuwong, Anna Wozniacka, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 5, 2026
Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality
Claudia Zeidler, Simone Garcovich, Svetlana Bobko, et al.
Expert Opinion on Biological Therapy
|
October 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial
Jacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Expert Opinion on Biological Therapy
|
July 25, 2025
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study
Jacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Acta Dermato-Venereologica
|
August 30, 2012
Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement
Masutaka Furue, Toshiya Ebata, Akihiko Ikoma, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 12, 2023
Classification of psychodermatological disorders: Proposal of a new international classification
Bárbara Roque Ferreira, Nienke Vulink, Ladan Mostaghimi, et al.
The British Journal of Dermatology
|
May 13, 2022
Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial
Mauro Picardo, Carla Cardinali, Michelangelo La Placa, et al.
International Wound Journal
|
August 5, 2024
Assessing health-related quality of life using the Wound-QoL-17 and the Wound-QoL-14-Results of the cross-sectional European HAQOL study using item response theory
Toni Maria Janke, Vlastimil Kozon, Skaidra Valiukeviciene, et al.
Allergy
|
January 9, 2025
CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study
Sarbjit S Saini, Marcus Maurer, Yevgeniya Dytyatkovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 24, 2023
White paper on psychodermatology in Europe: A position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP)
Laurent Misery, Christina Schut, Flora Balieva, et al.
Page
of 32
Search research articles
Search
Showing results (261-270 of 316) with videos related to
Sort By:
Page
of 32
Arthritis and Rheumatism
|
July 31, 2013
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus
Jacek C Szepietowski, Surasak Nilganuwong, Anna Wozniacka, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
June 5, 2026
Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality
Claudia Zeidler, Simone Garcovich, Svetlana Bobko, et al.
Expert Opinion on Biological Therapy
|
October 16, 2025
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial
Jacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Expert Opinion on Biological Therapy
|
July 25, 2025
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study
Jacek C Szepietowski, Adam Reich, Steven R Feldman, et al.
Acta Dermato-Venereologica
|
August 30, 2012
Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement
Masutaka Furue, Toshiya Ebata, Akihiko Ikoma, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 12, 2023
Classification of psychodermatological disorders: Proposal of a new international classification
Bárbara Roque Ferreira, Nienke Vulink, Ladan Mostaghimi, et al.
The British Journal of Dermatology
|
May 13, 2022
Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial
Mauro Picardo, Carla Cardinali, Michelangelo La Placa, et al.
International Wound Journal
|
August 5, 2024
Assessing health-related quality of life using the Wound-QoL-17 and the Wound-QoL-14-Results of the cross-sectional European HAQOL study using item response theory
Toni Maria Janke, Vlastimil Kozon, Skaidra Valiukeviciene, et al.
Allergy
|
January 9, 2025
CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study
Sarbjit S Saini, Marcus Maurer, Yevgeniya Dytyatkovska, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 24, 2023
White paper on psychodermatology in Europe: A position paper from the EADV Psychodermatology Task Force and the European Society for Dermatology and Psychiatry (ESDaP)
Laurent Misery, Christina Schut, Flora Balieva, et al.
Page
of 32